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Abstract 
Target therapy for oncologic diseases presents a big challenge for advance nanomedicine. In our work, we 
focused on multi-target approach development. Designed nanotransporter is based on polysaccharide 
chitosan which allows formation of nanoparticles. These nanoparticles can bind metal ions, mainly zinc 
(moreover, zinc stabilizes chitosan structure). The estimated zinc concentration was approximately 1 nmol/g 
of chitosan. In addition, chitosan nanoparticle (cage) irreversibly binds therapeutics which could be applied for 
targeted therapy of malignant tumours. Designed chitosan structure (LMQ, 10 g) encapsulation efficiency for 
doxorubicin was 50%. The pH change (tested interval 5 - 8) caused 20% release of doxorubicin from the 
nanocage. The nanotransporter is orientated to cancer tissue due the fact that the malignant cells highly 
express metallothionein (MT). The increased affinity of MT to zinc ions causes that the nanotransporter is 
preferentially bound to tumour regions with a high MT concentration. Our latest experimental results showed 
the changes in amino acid metabolism of prostate cancer signalized by increase in the amount of amino acid 
sarcosine. Therefore, the chitosan-based nanotransporter was modified by anti-sarcosine antibody. The 
functionality of designed nanotransporter was proved by ELISA with double detection of doxorubicin using 
fluorescence and by peroxidase activity of ABTS substrate. In another system, magnetic separation and 
identification of individual components of the nanotransporter were used. The sarcosine binding activity was 
estimated around 50%.  
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1. INTRODUCTION     
Nowadays, polymers are greatly used for biodegradable drug carrier due to its ability to gradual release of the 
therapeutic compound. Among natural polymers belongs chitosan gained from chitin. Chitosan is a cationic 
polymer and it has three reaction centers. The primary amino group tend to quaternization and it can bind 
metal ions. Primary hydroxy group is often substituted by “spacers” which leads to binding of drug active groups 
or targeting labels. Secondary hydroxy group could be modified for improving the chitosan solubility [1]. The 
chitosan oligomers can be partially attributed to the ionic cross-linking using polyanions resulting in 
nanoparticle formation [2]. Chitosan nanoparticles have attracted more attention in drug delivery due to their 
stability, low toxicity and easy preparation. Deacetylated chitosan skeleton composed of glucosamine units 
has a high density of charged amino groups which allow strong electrostatic interactions with biomolecules [3]. 
Several authors described doxorubicin encapsulation to the polymeric cage formed by chitosan. Doxorubicin 
is widely used anthracycline antibiotic for the cancer treatment. Although, doxorubicin shows serious side 




effects such as cardiotoxicity [4]. The development of new chitosan-based nanotransporters is aimed at 
reducing the cardiotoxicity of anthracycline antibiotics. Raja et al. published the pH-sensitive, self-assembled 
nanoparticles formed by N-acetyl histidine and arginine-grafted chitosan for doxorubicine delivery. Prepared 
nanocarriers shows good results in resistant human breast tumor cell line (MCF-7) efficiently in a dose-and 
time-dependent pattern [5]. Collagen peptide functionalized chitosan nanoparticles as a smart drug delivery 
carrier in advanced cancer therapy was presented by Anandhakumar et al. Observed nanoparticles showed 
stability under physiological conditions, high encapsulation efficiency towards doxorubicin hydrochloride as 
well as pH controlled release. Moreover, the excellent anti-proliferative characteristics against HeLa cells with 
favorable biocompatibility against normal cells have been proven [6]. Further modifications are described 
across the literature. We would like to highlight the myristate [7], Dextran-sulfate [8], folate [9], PEGylated 
liposome [10], glycyrrhetinic acid-modified chitosan-cystamine-poly(epsilon-caprolactone) copolymer [11], and 
stearic acid [12]. Summarily, the chitosan structure allows various modifications and functionalizations aimed 
to be a nanocarrier useful with unique properties beneficial in the cancer treatment. 
In our previous study we described DOX enclosed in chitosan nanoparticles functionalized by Zn2+ ions [13]. 
We observed the affinity of nanotransporter to metallohionein, which is overexpressed in the tumor tissue and 
plays an important role in breast cancer. In the further work, we want to focus on multi-targeted therapy 
provided by functionalized chitosan nanoparticles (CS NPs) by anti-sarcosine antibodies. For CS NPs 
stabilization we investigated the influence of zinc ions (Figure 1).  
 
Figure 1 The structure of chitosan-based nanotransporter in multi-target therapy in the prostate cancer 
treatment. Prostate tumor cells highly express amino acid sarcosine. Via anti-sarcosine antibodies is CS NPs 
nanotransporter targeted to the tumor cells. Nanocarrier decorated by zinc ions facilitate enhance retention 
permeability effect of CS NPs in the blood stream 




2. MATERIAL AND METHODS   
Chemicals 
Low molecular weight chitosan, sodium tripolyphosphate penta basic (TPP), DMSO, sodium acetate, acetic 
acid, doxorubicin HCl, zinc chloride and other chemicals unless noted otherwise were purchased from Sigma-
Aldrich (USA). Aqueous solutions analysis were prepared using Milli Q water from Millipore Systems (USA) 
with conductivity less than 0.2 mS/cm.  
Preparation of chitosan nanoparticles  
In the case of Zn inner type of CS NPs, 12.5 mg of low MW chitosan was dissolved in 5 mL of 1 % acetic acid. 
Doxorubicin (30 µM) and Zinc (0.5 m/mL) was added to the chitosan solution under stirring (3 hours, 24 °C). 
After chitosan dissolution the sodium tripolyphosphate (0.25 % w/v) was added dropwise and incubated in 
rotator Multi-Rotator RS-60 BIOSAN. Zn outer type NPs was prepared in the same way, however the Zinc (0.5 
mg/mL) was added after TPP gelatation. The mixture was stirred 3 hours, 24 °C. 
Ninyhdrin assay 
The reaction solutions were then processed as described in articles [14, 15]. The ninhydrin reagent was freshly 
prepared on the day of the assay by adding 25 ml of 4 M acetate buffer (pH 5.2) to 2 g ninhydrin and 0.3 g 
hydrindantin in 75 ml DMSO. For the assay, 75 µL of reagent was added to 100 µL of the sample in microtube. 
The microtubes were immediately capped, briefly shaken by hand and heated thermoblock for 30 min to allow 
the reaction to proceed. After cooling, 15 ml of a 50:50 ethanol:water mixture was added to each sample. The 
color intensity of the complex was spectrophotometrically evaluated as a measurement of depolymerized 
chitosan activity. Accurately weighed depolymerized chitosan was dissolved in 1% w/v acetic acid. A blank 
solution was also prepared in an identical manner, wherein 1% w/v acetic acid was used instead of a chitosan 
solution to prepare the reaction mixture. The effect of the solvent system was nullified by calibrating the 
instrument to 100% transmittance of the blank solution.  
Dot blot assay 
On the nitrocelulose membrane 0.45 µm pore diameter (SERVA, Heidelberg, Germany) was pippeted 1-2 µl 
of Rabbit AntiChicken antibody. After drying, the membrane was blocked with 1% BSA in PBS buffer. After 30 
min incubation in the rotator the membrane was soaked in the CSNPs (AntiSar/CS NPS/Dox-AuMNPs) 
solution for 1 hour. The incubation was carried out in the 50 ml tube on rotator (15 rpm). The membrane was 
3x washed using PBS-T. Further, the membrane was soaked in AuNPs labeled antibody or sarcosine for 1 
hour. Each sample was washed from unbounded parts by PBS-T buffer. After dying the membrane, the 
samples were prepared for evaluation.  
3. RESULTS 
Characterization of CS NPs  
For basic characterization of the formed nanoparticles spectrophotometric analysis based on the reaction of 
CS with ninhydrin solution have been used which enabled to react with primary and secondary amino groups. 
The chromophore is created by amine condensation with a molecule of ninhydrin to give Ruhemann purple. 
Firstly, the effects of several factors including the reaction temperature, reaction time and the ninhydrin 
concentration on the chitosan-ninhydrin reaction were investigated to optimize the specificity and sensitivity. 
Figure 2 A shows the dependence of absorbance on reaction temperature 70 - 100 °C, where the increase of 
chromophore absorbance in correlation with higher temperature in absorbance maxima is obvious. The 100 
°C of reaction temperature was used for testing the reaction time (0 - 60 min). Figure 2B shows increasing 
trend of signal in correlation with the increasing ninhydrin amount up to the concentration of 32 µg per reaction. 




Higher concentration caused slightly decrease in the signal. In the graph (Figure 2C) is clearly shown that the 
reaction time up to 40 min lead to the highest absorbance which were also stable after 50 and 60 min. The 
dependence of ninhydrin amount entering the reaction with CS was investigated. The dependence of 
absorbance on CS concentration (0-0.5 mg/mL) is shown in Figure 2D. Calculated limit of detection was 1.7 
µg/mL. 
We used ninhydrin assay to monitor of chitosan properties in the presence of TPP and zinc. As we described 
in the introduction, TPP as well as zinc ions stabilize chitosan crosslinked structure and provide nanoparticle 
formation. We studied the dependence of various CS concentrations 0.06 - 2.00 mg/mL in the presence of  
2 mg/mL TPP. The low CS concentration in the presence of TPP showed similar signal intensity as CS alone. 
Up to the CS concentration of 0.5 mg/mL it was evident that the signal intensity of TPP was lower than CS 
alone. The CS NPs were well formed in the concentration of 2 mg/mL of CS and the higher TPP concentration 
caused its stabilization. The apparent signal intensity of CS NPs decreases in the dependence of higher TPP 
concentration that results in more crosslinked structure. 
 
Figure 2 Optimization the ninhydrin assay: A) reaction temperature (70-100 °C), B) ninhydrin amount per 
reaction (12-40 µg). C) reaction time (0-60 min). D) Dependence of CS concentration (0-0.6 mg/mL) on 
absorbance 
Doxorubicin release in pH range (5-8) 
In our experiment, we studied the stability of CS NPs and doxorubicin release in the intervals from several 
hours to several days. For 28 hours CS NPs were subjected to doxorubicin (DOX) fluorescence sensing and 
the cumulative release of DOX amount were calculated in selected environmental conditions: blood, phosphate 




buffer (1 mM) pH 5, 7 and 8. Results clearly showed the rapid DOX release which began immediately and 
ended after 120 min. Further DOX release was not so intensive and the NPs were stable. Apparent differences 
between each environment showed the highest stability of CS NPs at pH 5. The strongest cumulative release 
of DOX amount occured in the blood environment. Not surprisingly, blood is complex matrix and the presence 
of enzymes, proteins and specific components caused the rapid DOX release from CS nanostructure. 
AntiSar antibody - CS NPs conjugation 
Our goal was to design a nanocarrier which can target into the cancer tissue with highly expressed levels of 
sarcosine, such as prostate cancer. We utilized non-specific conjugation of chicken AntiSar antibody to CS 
NPs surface. This interaction is mediated by electrostatic and hydrophobic interactions between positively 
charged CS and proteins. For the verification of this interaction, we employed the dot blot analysis as a rapid 
and precise immunochemical method. We utilized the ability of AuNPs aggregation which was visible as a 
purple dot on the membrane. After initiation of primary antibodies, the membrane surface was blocked by 
bovine serum albumin (BSA) to avoid false positive results. The dot blot analysis showed positive signal in 
both cases; control sample (labeled AntiSar antibodies) and the CS-AntiSar NPs. From this result, we assume 
that the proposed system is applicable and we can proceed with chitosan testing itself. The chicken AntiSar 
antibodies were attached on the surface of CS NPs. The formation of this complex was confirmed by the 
interaction with AuNPs labeled sarcosine (AuSar). The stronger interaction was occurred when primary rabbit 
AntiChicken antibodies was immobilized on the membrane. We continued with the sandwich method and the 
CS NPs-AntiSar labelled with rabbit AntiChicken-AuNPs showed the strong positive reaction. This effect is due 
to a stronger binding of the first antibody to the second antibody.  
4. CONCLUSION 
A detailed interaction study of chitosan nanotransporter, zinc ions and TPP has been performed. The Zn2+ 
concentration shows the strong effect on crosslinking and coiling of CS NPs with the result of better 
nanoparticle stabilization. The entrapment efficiency for doxorubicin of designed CS NPs was 20%. The 
highest drug release from the CS nanocarrier appeared after 120 min at the pH 5, 6, 8 and in blood 
environment. Functionality and ability  of the AntiSar/CS NPs/DOX binding to the sarcosine molecule was 
proved by dot blot analysis. 
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